Instil Bio to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Instil Bio (Nasdaq: TIL) announced its management will present an overview at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 9:30 a.m. ET. Interested parties can access a live webcast at here. Instil is focused on developing TIL therapies, advancing products like ITIL-168 and ITIL-306 for cancer treatment, particularly advanced melanoma and solid tumors.

DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 9:30 a.m. ET.

A live webcast of the presentation may be accessed at: https://wsw.com/webcast/jeff174/til/1707183 or by visiting the News & Events section of the Instil Bio website at www.instilbio.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

About Instil Bio

Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. Instil has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.

Contacts:

Investor Relations 1-972-499-3350 investor.relations@instilbio.com www.instilbio.com Brendan Payne Stern Investor Relations 1-212-362-1200 brendan.payne@sternir.com

FAQ

When will Instil Bio present at the Jefferies Virtual Healthcare Conference?

Instil Bio will present on June 4, 2021, at 9:30 a.m. ET.

How can I access the Instil Bio presentation webcast?

The webcast can be accessed live at Instil Bio's website or directly through the provided link in the press release.

What therapies is Instil Bio developing?

Instil Bio is developing tumor infiltrating lymphocyte (TIL) therapies, including ITIL-168 and ITIL-306, for treating cancer.

What is the focus of Instil Bio as a biopharmaceutical company?

Instil Bio focuses on developing TIL therapies for cancer treatment, particularly for advanced melanoma and other solid tumors.